X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Aczone contains dapsone, a sulfone, in an aqueous gel base indicated for the topical treatment of acne vulgaris. It works by killing or preventing the growth of bacteria on the skin.
Lead Product(s): Dapsone
Therapeutic Area: Dermatology Product Name: Aczone-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: SeegPharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
PULM-001 data shown to prevent and treat acute respiratory distress syndrome due to SARS-CoV-2 infection and reduce mortality from 40% to 0% in a small, randomized clinical trial.
Lead Product(s): Dapsone
Therapeutic Area: Infections and Infectious Diseases Product Name: PULM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2021
Details:
PULM-001 is a decades-old, safe and affordable oral antibacterial that also has well-recognized anti-inflammatory properties. It has been used to treat infectious diseases such as malaria, lupus, HIV and many other inflammatory infections.
Lead Product(s): Dapsone
Therapeutic Area: Infections and Infectious Diseases Product Name: PULM-001
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
Research found that eight-week course of the proven leprosy drug dapsone combined with doxycycline and rifampin is effective in improving symptoms in 98% of patients suffering from chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS).
Lead Product(s): Dapsone,Doxycycline,Rifampicin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2020
Details:
The Phase III Clinical Trial is sponsored by the Research Institute of the McGill University Health Centre (RI-MUHC) and will be conducted in seven centres in Canada and the United States as soon as the necessary funding has been secured.
Lead Product(s): Dapsone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: McGill University Health Centre
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
